Rohman Nur, Ardiansah Bayu, Wukirsari Tuti, Judeh Zaher
Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok 16424, Indonesia.
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 62 Nanyang Drive, N1.2-B1-14, Singapore 637459, Singapore.
Molecules. 2024 Feb 27;29(5):1026. doi: 10.3390/molecules29051026.
Molecular hybridization represents a new approach in drug discovery in which specific chromophores are strategically combined to create novel drugs with enhanced therapeutic effects. This innovative strategy leverages the strengths of individual chromophores to address complex biological challenges, synergize beneficial properties, optimize pharmacokinetics, and overcome limitations associated with single-agent therapies. Coumarins are documented to possess several bioactivities and have therefore been targeted for combination with other active moieties to create molecular hybrids. This review summarizes recent (2013-2023) trends in the synthesis of coumarins, as well as coumarin-chalcone and coumarin-triazole molecular hybrids. To cover the wide aspects of this area, we have included differently substituted coumarins, chalcones, 1,2,3- and 1,2,4-triazoles in this review and considered the point of fusion/attachment with coumarin to show the diversity of these hybrids. The reported syntheses mainly relied on well-established chemistry without the need for strict reaction conditions and usually produced high yields. Additionally, we discussed the bioactivities of the reported compounds, including antioxidative, antimicrobial, anticancer, antidiabetic, and anti-cholinesterase activities and commented on their IC where possible. Promising bioactivity results have been obtained so far. It is noted that mechanistic studies are infrequently found in the published work, which was also mentioned in this review to give the reader a better understanding. This review aims to provide valuable information to enable further developments in this field.
分子杂交是药物发现中的一种新方法,其中特定的发色团经过策略性组合以创造出具有增强治疗效果的新型药物。这种创新策略利用单个发色团的优势来应对复杂的生物学挑战,协同有益特性,优化药代动力学,并克服与单药疗法相关的局限性。有文献记载香豆素具有多种生物活性,因此已成为与其他活性部分结合以创造分子杂化物的目标。本综述总结了近期(2013 - 2023年)香豆素、香豆素 - 查尔酮和香豆素 - 三唑分子杂化物的合成趋势。为了涵盖该领域的广泛内容,我们在本综述中纳入了不同取代的香豆素、查尔酮、1,2,3 - 和1,2,4 - 三唑,并考虑了与香豆素的融合/连接点以展示这些杂化物的多样性。报道的合成方法主要依赖成熟的化学方法,无需严格的反应条件,且通常产率较高。此外,我们讨论了所报道化合物的生物活性,包括抗氧化、抗菌、抗癌、抗糖尿病和抗胆碱酯酶活性,并在可能的情况下对其半数抑制浓度进行了评论。到目前为止已经获得了有前景的生物活性结果。需要注意的是,在已发表的工作中很少发现机理研究,本综述中也提到了这一点,以便读者更好地理解。本综述旨在提供有价值的信息,以推动该领域的进一步发展。